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Purpose/Objective: Cambridge University Hospitals (CUH) has been 
routinely treating patients with Head & Neck Squamous Cell 
Carcinoma with Image-Guided/Intensity Modulated Radio Therapy 
(IG/IMRT) using helical arc therapy (HAT) since 2008. We compared 
outcomes for patients with oropharyngeal cancer treated using HAT 
with historical control cohorts treated using conformal radiotherapy 
techniques or 'step and shoot' IMRT delivered on a conventional linear 
accelerator. 
Materials and Methods: We retrospectively reviewed patients treated 
radically with radiotherapy for primary oropharyngeal squamous cell 
carcinoma at CUH between April 2002 and April 2010 (recurrent 
disease, non-squamous pathology or palliative treatment were 
excluded). 183 patients were identified for whom sufficient data 
could be demonstrated, 141 (77%) were male and 42 (23%) female. 
Median age at diagnosis was 58 years (range 30 - 83). Commonest site 
for primary tumour was tonsil (95 patients, 51.9%) followed by tongue 
base (68 patients, 37.2%). Most patients treated were stage 3 (35 – 
19.2%) or stage 4 (127 - 69.7%). 62 patients underwent neck surgery - 
59 patients (32.2%) had unilateral neck dissection, 3 (1.6%) had 
bilateral nodal clearance. 95 patients (52%) had concomitant 
chemoradiotherapy (cisplatin or cetuximab) and only 3 patients (1.6%) 
had induction chemotherapy. Over 90% of patients were treated to 68 
Gy in 34 daily fractions over seven weeks. Other schedules, each used 
for 5 patients or less, included 70 Gy in 35 #, 65 Gy in 30 # and 55 Gy 
in 20 #.  Conformal radiotherapy was used for 111 (60.6%) patients 
between 2002 & 2008, 17 (9.3%) had IMRT delivered on a conventional 
linac (2007-09) and 55 patients (30.1%) were treated with helical arc 
therapy (2008-10). The patients treated by each method had similar 
distributions of age, disease site and stage, and similar numbers 
underwent neck surgery. Increasing use of concomitant 
chemoradiotherapy was evident (41.8% in conformal group, 64.7% in 
IMRT group and 74.5% in HAT group).  
Results: Median follow-up was 4.4 years and for the 'conformal RT', 
'IMRT' and 'HAT' groups was 5.6, 3.7 and 3.2 years, respectively. 
Kaplan-Meier survival probability estimates for recurrence-free 
survival and overall survival at two years showed improved results for 
patients treated with HAT compared to patients treated using our 
prior techniques. HAT also resulted in a lower ratio of loco-regional 
recurrence to distant relapse suggesting effective primary disease 
control. T-stage was a strong prognostic indicator and is associated 





Conclusions: Local control and overall survival statistics for patients 
with oropharyngeal cancer treated at Cambridge University Hospitals 
using HAT and concomitant chemotherapy were better than for 
historic controls. Tumour T-Stage at diagnosis was a strong prognostic 
indicator for both disease-free and overall survival at two years. 
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Purpose/Objective: To investigate the prognostic effect of tumor 
volume on patients with advanced nasopharyngeal carcinoma (NPC). 
Materials and Methods: From February 2000 to June 2006, a total of 
181 patients with biopsy-proven NPC, no distant metastasis, and 
available pre-treatment magnetic resonance imaging were 
retrospectively reviewed. Most of the patients (95.6%) had stage III/IV 
diseases. All patients were treated by 10-weekly neoadjuvant 
chemotherapy and radiotherapy. We delineated the contour of the 
primary tumor, retropharyngeal and neck nodes. The tumor volume 
was calculated by the EclipseTM treatment planning software. PTV, 
NTV, TTV indicated tumor volumes of primary site, regional nodes, 
and total tumor. The end-points included subsequent distant failure 
rates, nasopharynx failure-free survival (NPFFS), distant metastasis 
failure-free survival (DMFFS), relapse-free survival (RFS) and overall 
survival (OS). 
Results: After a minimal follow-up of 60 months for living patients, 
there were 55 failures – 8 in primary, 3 in regional, 34 in distant, 2 in 
primary+ regional, 6 in primary+ distant, 1 in regional+ distant, and 1 
in primary+ regional + distant sites. The PTV and NTV were positively 
correlated withT-stage and N-stage (P<0.0001). The range of TTV was 
7.99 – 323.65 cm3, with a median of 52.33 cm3and a mean of 66.45 
cm3.The median TTV of stage II, III, and IV were 28.28, 38.81, and 
68.06 cm3respectively (P<0.0001). PTV affects NPFFS (P=0.0252) and 
OS (P=0.0281) significantly. NTV affects DMFFS (P<0.0001) and OS 
(P=0.0028)significantly. Patients with tumor relapse had significantly 
higher TTV than those without relapse (median 45.95 vs. 69.53 cm3, 
P<0.0001). The tumor relapse rates between the patients with TTV ? 
and < 54.96 cm3 were 47.0% (39/83) and 16.3%(16/98), respectively 
(P<0.001).The distant failure rates between the patients with TTV ? 
and < 54.96 cm3 were 37.3% (31/83) and 11.2%(11/98), respectively 
(P<0.001).The rates of 7-year DMFFS, RFS, and OS in patients with TTV 
? 54.96 cm3 were significantly lower than those with TTV < 54.96 
cm3.The TTV also affect NPFFS with a borderline significance 
(P=0.0553). 
Conclusions: PTV is correlated with T-stage and affects NPFFS and OS. 
NTV is correlated with N-stage and affects DMFFS and OS. TTV is 
correlated with overall stage and has a significant effect on tumor 
relapses and patient survivals in advanced NPC. 
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Purpose/Objective: To analyse the patterns of locoregional (LR) 
failure in patients (pts) with head-and-neck cancer (HNC) treated with 
intensity-modulated radiotherapy (IMRT) aiming to spare the parotid 
glands (PG) the submandibular glands (SMG) and the accessory salivary 
glands represented by the oral cavity (OC). 
Materials and Methods: Between September 2009 and August 2011, 70 
consecutive pts with squamous cell HNC treated with definitive 
bilateral neck IMRT were included. The disease was stage III-IV and 
stage I-II in 77% and 23% of pts respectively. The primary tumor site 
was the OC (8 pts), oropharynx (31 pts), hypopharynx (17pts), larynx 
(10 pts), nasopharynx (3 pts), and 1 patient had unknown primary 
tumor. A simultaneously integrated boost (SIB) technique with 3 dose 
levels (PTV70-66, PTV63-60, PTV56-54 Gy) was used. 69% of pts 
received a concomitant treatment. The FDG-PET and CT scan of the 
recurrence were fused with the initial planning CT. Contours of the 
failure volumes (Vf) were defined taking into account all clinical 
examination, radiological imaging and histological information. 
Failures were categorized as 'in-field' if more than 95% of the Vf was 
covered by 95% of the prescription dose, 'marginal' if 20% to 95% of the 
Vf was encompassed by 95% of the prescription dose, and 'out-of-field' 
if less than 20% was contained within the 95% dose. Dose-volume 
histograms were calculated to analyse the dose received by Vf. The 
doses delivered in the salivary glands and OC spared were assessed. 
Xerostomia was assessed according to Radiation Therapy Oncology 
Group (RTOG) criteria. 
Results: With a median follow-up of 20 months (range: 6-35), the 2-
years LR control and overall survival rates were 76.5% (95% confidence 
2nd ESTRO Forum 2013   S255 
interval [CI]: 64-89%) and 95.8% (95% CI: 90-100%) respectively. 
Thirteen pts presented LR failures, of which 4 had isolated local 
failure, 4 had isolated regional failure, 2 had local and regional 
failures, and 3 had simultaneous LR and distant relapses. Of 13 pts 
with LR relapse, only 1 (8%) had marginal failure, with the remaining 
92% failing truly in-field within the high-dose region. No patient 
recurred in vicinity of spared PG, SMG or OC. Surgical salvage for LR 
failure was attempted in 5 pts. Contralateral PG was spared in 98% of 
pts and ipsilateral PG in 54%. Concerning SMGs, 18 (26%) contralateral 
glands were spared and the ipsilateral SMG was spared in 5 pts. In 
other 13 (19%) pts doses to the SMGs below 50 Gy were obtained. The 
OC was spared to a dose ≤40 Gy in 26 pts (37%). None of the pts 
developed permanent xerostomia higher than grade 2 at the last 
follow-up visit. 
Conclusions: The majority of LR failures occurred in-field within the 
high dose region. Sparing SMGs and OC in addition to PGs does not 
seem to jeopardize the LR control in HNC IMRT.  
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Purpose/Objective: To evaluate the role of pretreatment dual-phase 
18F-FDG-PET maximum standardized uptake (SUVmax) in predicting 
the outcome of nasopharyngeal carcinoma (NPC). 
Materials and Methods: A total of 140 patients with newly diagnosed 
NPC were prospectively treated with IMRT plus neoadjuvant or 
concurrent chemotherapy between January 2006 and December 2008. 
Pretreatment SUVmax at 60 minutes (SUV1) and 150 minutes (SUV2) 
after injection of 18F-FDG were collected. We investigated the effects 
of SUVmax of primary tumor (SUV1-primary, SUV-2-primary) and neck 
lymph nodes (SUV1-neck, SUV2-neck) on locoregional failure-free 
survival (LRFFS), distant metastasis failure-free survival (DMFFS) and 
overall survival (OS). 
Results: In univariate analysis, the 5-year rate of OS for patients with 
SUV1-primary <12.9 was significantly higher than those with SUV1-
primary ?12.9 (87.0% and 72.2%, p=0.044). SUV2-primary, SUV1-neck 
and SUV2-neck did not affect OS significantly. All SUVs of primary 
tumor and neck lymph nodes have significant effects on DMFFS (SUV1-
primary < vs. ?12.5=89.1% vs. 70.8%, p=0.004; SUV2-primary < vs. 
?12.8=88.6% vs. 76.4%, p=0.022; SUV1-neck < vs. ?8.1=91.0% vs. 71.8%, 
p=0.003; and SUV2-neck < vs. ?3.7=94.7% vs. 80.5%, p=0.024, 
respectively). All SUVs had no significant effect on LRFFS. In 
multivariate analysis, except for N stage, SUV1-primary, SUV2-primary 
and SUV1-neck were significantly independent predictors of DMFFS 
(hazard ratio=4.313, 95% CI=1.447~12.855, p=0.009; hazard 
ratio=4.399, 95% CI=1.514~12.785, p=0.006; and hazard ratio=3.769, 
95% CI=0.985~14.420, p=0.053, respectively). 
Conclusions: The SUV1- primary predicts OS by univariate analysis. 
The SUV1-primary, SUV2-primary and SUV1-neck were independently 
prognostic factors of distant failure.  
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Purpose/Objective: To create Helical Tomotherapy (HT) plans for t 
treating patients with oropharyngeal cancer (OPC) with the same 
treatment time as RapidArc (RA) Volumetric Modulated Arc Therapy 
(VMAT).  
Materials and Methods: We made both a double arc RA plan on 
Eclipse and a standard HT plan on TomoHDTM according to the ICRU 83 
guidelines in 5 OPC patients. In 32 fractions, a simultaneous 
integrated boost technique was planned to deliver 69.12 Gy (2,16 Gy / 
fraction) to the high risk volume (PTV of the GTV + 1cm) and 56 Gy 
(1.75 Gy / fraction) to the PTV of the remaining primary tumor region 
and the bilateral elective lymph node regions. Guidelines for all the 
organs at risk (OARs) were given. By modifying the beam width from 
2.5 cm to 5.0 cm, elevating the pitch and lowering the modulation 
factor, we created 'Tomo Fast (TF) plans in which treatment times 
were equal to those in the RA plans. The homogeneity index (HI), the 
conformity index (CI), the mean dose, the Dnear-max (D2) and the 
Dnear-min (D98) of the PTVs were analyzed as well as the mean dose 
and specific critical doses and volumes of 26 OARs . Differences 
between the individual plans of the treatment planning systems were 
analyzed using repeated measures ANOVA. 
Results: With a mean treatment time of 3.05 min for RA and 2.89 min 
for TF , PTVboost coverage was more homogeneous with TF (mean HI 
.07; SE .01) than with RA (mean HI .10; SE .01). while PTVelective was 
most homogeneous with RA. Mean doses to the parotid glands were 
identical for RA and TF: 25.62 Gy and 25.34 Gy for the contralateral 
and 32.02 Gy and 31.96 Gy for the ipsilateral gland, respectively. 
Spinal cord, cricopharyngeal muscle and cranial part of the esophagus 
received a lower mean dose when planned with TF, the glottic larynx 
when planned with RA. V20 of the lungs, mean dose of inner ears, 
brain and eyes, and the integral dose were higher with TF than with 
RA, probably due the 5 cm beam width related cranial-caudal gradient 
extension. For details, see enclosed Table. 
 
  
Conclusions: This study shows that it is possible to treat OPC patients 
with TF as fast as with RA while giving comparable target coverage 
and sparing of most critical organs. However, with TF the higher dose 
to the organs at the cranial and caudal end of the target volume and 
the higher integral dose, both due to the extended cranial-caudal 
gradient, needs consideration. Moreover, compared to regular HT, 
both these faster techniques lose a (major) part of HT’s OAR sparing 
capacity. 
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Purpose/Objective: Optimisation of swallowing outcome after 
curative radiotherapy is multifaceted and requires maintaining the 
functional integrity of multiple pharyngeal axis structures. Recent 
dose/volume/outcome data (DVO)demonstrates a correlation between 
laryngeal dose and late dysphagia complication. Accurate and reliable 
DVO data demands consistent delineation, yet several guidelines for 
the delineation of the pharyngeal axis exist. This is a comparative 
study of two delineation guidelines of the pharyngeal axis and the 
implications that differences between them may have on dosimetry.  
Materials and Methods: The pharyngeal axis (inclusive of superior 
(SPCM), middle (MPCM) and inferior pharyngeal constrictors (IPCM), 
cricopharyngeus(CP), oesophageal inlet (OI)) were retrospectively 
contoured by one clinician on five consecutive patients with SCC head 
and neck, utilising two different sets of delineation guidelines (G1 (1) 
